Outcomes and Usability of Formoterol-Budesonide Delivered Through Synchrobreathe® in Patients With Chronic Obstructive Pulmonary Disease: The EMERGE Study

20250 citationsJournal Articlegold Open Access

Authors

Santhalingam Balamurugan · ACS Medical College and Hospital

Himanshu Pophale · Maharashtra Association of Anthropological Sciences

Utsav Samariya · Central University of Tibetan Studies

Komalkirti Apte · Excell Research (United States)

Sheetu Singh · Rajasthan Dental College and Hospital

Raja Dhar · AMRI Hospitals

Sujeet Rajan

Abstract

BUD/FORM delivered through Synchrobreathe<sup>®</sup> significantly improved CAT and mBDS scores, with no reported serious adverse events in patients with COPD. Its simple usage makes it an effective option for this patient population.

Topics & Keywords

Chronic Obstructive Pulmonary Disease (COPD) Research Respiratory and Cough-Related Research Asthma and respiratory diseases

Publication Details

Published in: Drugs - Real World Outcomes

Volume 12, Issue 4, pp. 643-654

DOI: 10.1007/s40801-025-00522-w

Field-Weighted Citation Impact: 0.00

Command Palette

Outcomes and Usability of Formoterol-Budesonide Delivered Through Synchrobreathe® in Patients With Chronic Obstructive Pulmonary Disease: The EMERGE Study

Authors

Abstract

Topics & Keywords

Publication Details